These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 23639510)
21. Magnetic resonance imaging of the pancreas in streptozotocin-induced diabetic rats: Gadofluorine P and Gd-DOTA. Cho HR; Lee Y; Doble P; Bishop D; Hare D; Kim YJ; Kim KG; Jung HS; Park KS; Choi SH; Moon WK World J Gastroenterol; 2015 May; 21(19):5831-42. PubMed ID: 26019447 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of methotrexate-conjugated gadolinium(III) for cancer diagnosis and treatment. Xu D; Lu ST; Li YS; Baidya A; Mei H; He Y; Wu B Drug Des Devel Ther; 2018; 12():3301-3309. PubMed ID: 30323562 [TBL] [Abstract][Full Text] [Related]
23. A dual magnetic resonance imaging/fluorescent contrast agent for Cathepsin-D detection. Ta R; Suchy M; Tam JH; Li AX; Martinez-Santiesteban FS; Scholl TJ; Hudson RH; Bartha R; Pasternak SH Contrast Media Mol Imaging; 2013; 8(2):127-39. PubMed ID: 23281285 [TBL] [Abstract][Full Text] [Related]
24. Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent. Zhang W; Liang X; Zhang X; Tong W; Shi G; Guo H; Jin Z; Tian J; Du Y; Xue H Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1841-1855. PubMed ID: 38372766 [TBL] [Abstract][Full Text] [Related]
25. Synthesis and characterization of a cell-permeable bimodal contrast agent targeting β-galactosidase. Keliris A; Ziegler T; Mishra R; Pohmann R; Sauer MG; Ugurbil K; Engelmann J Bioorg Med Chem; 2011 Apr; 19(8):2529-40. PubMed ID: 21459584 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine. Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243 [TBL] [Abstract][Full Text] [Related]
27. The interplay of T1- and T2-relaxation on T1-weighted MRI of hMSCs induced by Gd-DOTA-peptides. Cao L; Li B; Yi P; Zhang H; Dai J; Tan B; Deng Z Biomaterials; 2014 Apr; 35(13):4168-74. PubMed ID: 24560458 [TBL] [Abstract][Full Text] [Related]
28. Dynamic contrast-enhanced MRI in mouse tumors at 11.7 T: comparison of three contrast agents with different molecular weights to assess the early effects of combretastatin A4. Fruytier AC; Magat J; Neveu MA; Karroum O; Bouzin C; Feron O; Jordan B; Cron GO; Gallez B NMR Biomed; 2014 Nov; 27(11):1403-12. PubMed ID: 25323069 [TBL] [Abstract][Full Text] [Related]
29. New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. Cyran CC; Fu Y; Raatschen HJ; Rogut V; Chaopathomkul B; Shames DM; Wendland MF; Yeh BM; Brasch RC J Magn Reson Imaging; 2008 Mar; 27(3):581-9. PubMed ID: 18219614 [TBL] [Abstract][Full Text] [Related]
30. Oval window transport of Gd-dOTA from rat middle ear to vestibulum and scala vestibuli visualized by in vivo magnetic resonance imaging. Zou J; Poe D; Ramadan UA; Pyykkö I Ann Otol Rhinol Laryngol; 2012 Feb; 121(2):119-28. PubMed ID: 22397222 [TBL] [Abstract][Full Text] [Related]
31. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats. Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739 [TBL] [Abstract][Full Text] [Related]
32. An intravascular MRI contrast agent based on Gd(DO3A-Lys) for tumor angiography. Yang CT; Chandrasekharan P; He T; Poh Z; Raju A; Chuang KH; Robins EG Biomaterials; 2014 Jan; 35(1):327-36. PubMed ID: 24138829 [TBL] [Abstract][Full Text] [Related]
33. In vivo MR/optical imaging for gastrin releasing peptide receptor of prostate cancer tumor using Gd-TTDA-NP-BN-Cy5.5. Lin YH; Dayananda K; Chen CY; Liu GC; Luo TY; Hsu HS; Wang YM Bioorg Med Chem; 2011 Feb; 19(3):1085-96. PubMed ID: 20493715 [TBL] [Abstract][Full Text] [Related]
34. A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent. Ye Z; Zhou Z; Ayat N; Wu X; Jin E; Shi X; Lu ZR Contrast Media Mol Imaging; 2016; 11(1):32-40. PubMed ID: 26218648 [TBL] [Abstract][Full Text] [Related]
35. Heat-activated liposomal MR contrast agent: initial in vivo results in rabbit liver and kidney. McDannold N; Fossheim SL; Rasmussen H; Martin H; Vykhodtseva N; Hynynen K Radiology; 2004 Mar; 230(3):743-52. PubMed ID: 14764890 [TBL] [Abstract][Full Text] [Related]
36. [Gadolinium-loaded nanoparticle as a novel molecular imaging contrast agent for magnetic resonance imaging]. Liu LZ; Guo GJ; Zeng MS; Lü YC; Liu XW; Cui CY; Wu PH; Li L Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(4):240-3. PubMed ID: 17425867 [TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo comparative performance studies of gadolinium-loaded zeolites and Gd-DOTA as contrast agents for MRI applications. Contro J; Silva DA; Santisteban OAN; Narayana PA; Nery JG J Biomed Mater Res B Appl Biomater; 2021 Aug; 109(8):1105-1115. PubMed ID: 33283412 [TBL] [Abstract][Full Text] [Related]
38. Polyion complex micelle MRI contrast agents from poly(ethylene glycol)-b-poly(l-lysine) block copolymers having Gd-DOTA; preparations and their control of T(1)-relaxivities and blood circulation characteristics. Shiraishi K; Kawano K; Maitani Y; Yokoyama M J Control Release; 2010 Dec; 148(2):160-7. PubMed ID: 20804796 [TBL] [Abstract][Full Text] [Related]
39. Gd-DOTA conjugate of RGD as a potential tumor-targeting MRI contrast agent. Park JA; Lee JJ; Jung JC; Yu DY; Oh C; Ha S; Kim TJ; Chang Y Chembiochem; 2008 Nov; 9(17):2811-3. PubMed ID: 18956393 [No Abstract] [Full Text] [Related]
40. [A comparative study between Gd-BOPTA, a biliary excretion contrast medium, and Gd-DTPA in the magnetic resonance imaging of the rat liver]. Patrizio G; Pavone P; Cardone G; Pietroletti R; Passariello R; Tettamanti E; Musu C; Felder E Radiol Med; 1990 May; 79(5):458-62. PubMed ID: 2359853 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]